Virtus Biotech Clinical Trials ETF
19 hedge funds and large institutions have $42.1M invested in Virtus Biotech Clinical Trials ETF in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 1 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
7% more capital invested
Capital invested by funds: $39.5M → $42.1M (+$2.58M)
6% more funds holding
Funds holding: 18 → 19 (+1)
4.14% more ownership
Funds ownership: 50.58% → 54.72% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$4.72M |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$535K |
| 3 |
Morgan Stanley
New York
|
+$467K |
| 4 |
VF
Virtu Financial
New York
|
+$370K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$2.59M |
| 2 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$36.4K |
| 3 |
JP Morgan Chase
New York
|
-$6K |
BBC Hedge Fund Activity: Q2 2018 in Review
19 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2018, worth a combined $42.1M — up 6.5% from $39.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBC positions and 1 closed out — a net gain of 1 holder — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $4.72M. The largest seller was United Capital Financial Advisors, cutting an estimated $2.59M.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2018, up from 18 in Q1 2018.
- Funds reported $42.1M of Virtus Biotech Clinical Trials ETF stock for Q2 2018, up 6.5% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q2 2018 and 1 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2018 was Envestnet Asset Management, an estimated $4.72M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q2 2018 was United Capital Financial Advisors, an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2018.